14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $14.58 $20.11 Thursday, 2nd May 2024 DNLI stock ended at $16.81. This is 4.02% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 6.41% from a day low at $15.92 to a day high of $16.94.
90 days $14.58 $23.52
52 weeks $14.58 $33.31

Historical Denali Therapeutics Inc. prices

Date Open High Low Close Volume
Dec 07, 2023 $19.10 $19.27 $18.29 $18.74 1 085 059
Dec 06, 2023 $18.55 $19.62 $18.46 $19.14 1 061 640
Dec 05, 2023 $18.59 $18.63 $18.24 $18.54 557 706
Dec 04, 2023 $18.83 $19.34 $18.33 $18.77 732 032
Dec 01, 2023 $18.38 $19.01 $17.88 $18.97 771 394
Nov 30, 2023 $18.66 $18.92 $18.12 $18.52 1 236 562
Nov 29, 2023 $18.45 $19.05 $18.34 $18.39 602 708
Nov 28, 2023 $17.97 $18.37 $17.50 $18.32 804 549
Nov 27, 2023 $18.26 $18.33 $17.50 $17.94 778 459
Nov 24, 2023 $18.01 $18.64 $18.01 $18.41 406 522
Nov 22, 2023 $18.58 $18.81 $17.92 $18.10 684 440
Nov 21, 2023 $18.74 $18.74 $18.10 $18.21 818 220
Nov 20, 2023 $18.86 $19.59 $18.60 $19.19 616 025
Nov 17, 2023 $18.41 $19.08 $18.07 $18.76 1 025 150
Nov 16, 2023 $18.45 $18.48 $17.37 $18.13 908 803
Nov 15, 2023 $19.13 $19.46 $18.40 $18.48 1 637 194
Nov 14, 2023 $16.92 $19.15 $16.92 $19.13 2 075 731
Nov 13, 2023 $15.92 $16.24 $15.45 $16.20 1 109 604
Nov 10, 2023 $17.15 $17.15 $15.92 $16.22 1 834 327
Nov 09, 2023 $20.40 $20.40 $16.95 $17.11 1 742 456
Nov 08, 2023 $20.04 $20.89 $18.96 $20.18 1 165 738
Nov 07, 2023 $20.80 $21.23 $20.42 $21.23 739 826
Nov 06, 2023 $21.86 $22.00 $20.62 $20.75 796 600
Nov 03, 2023 $20.18 $22.49 $20.18 $21.83 1 554 493
Nov 02, 2023 $19.32 $19.65 $18.89 $19.59 863 250
Click to get the best stock tips daily for free!

About Denali Therapeutics Inc.

Denali Therapeutics. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for ... DNLI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT